title: Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors.
abstract: Class B G-protein-coupled receptors are a small family of 15 peptide-binding receptors. This family includes at least six biologically attractive therapeutic targets for both peptide ligands (osteoporosis and Type II diabetes) and nonpeptide ligands (anxiety, depression and migraine). A general mechanism of peptide binding has emerged for this receptor family, termed the two-domain model. In this mechanism, the C-terminal ligand region binds the extracellular N-terminal domain of the receptor. This interaction acts as an affinity trap, promoting interaction of the N-terminal ligand region with the juxtamembrane domain of the receptor. Peptide binding to the juxtamembrane domain activates the receptor and stimulates intracellular signaling. Nonpeptide ligands bind the juxtamembrane or N-terminal domain and, in most cases, allosterically modulate peptide-ligand binding. Here, these mechanisms of peptide and nonpeptide ligand binding are reviewed, then applied in a discussion of the future strategies of drug development for Class B G-protein-coupled receptors.
authors.affiliation: Department of Pharmacology Neurocrine Biosciences, 12790 El Camino Real, San Diego, CA 92130, USA. shoare@neurocrine.com
authors.forename: Sam R J
authors.initials: SR
authors.lastname: Hoare
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D015195:Drug Design; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D010455:Peptides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D017434:Protein Structure, Tertiary; D043562:Receptors, G-Protein-Coupled / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*
chemical_list: D008024:Ligands; D010455:Peptides; D043562:Receptors, G-Protein-Coupled